ArticleInflammation2014
Topical corticosteroids do not revert the activated phenotype of eosinophils in eosinophilic esophagitis but decrease surface levels of CD18 resulting in diminished adherence to ICAM-1, ICAM-2, and endothelial cells.
Article in Inflammation, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- Minimally invasive biomarker studies in eosinophilic esophagitis: A systematic review.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2018Pooled it
- Investigating immune profile by CyTOF in patients with eosinophilic esophagitis after treatment with orodispersible budesonide.Clinical and experimental immunology · 2024Article
- The presence of serum anti-SARS-CoV-2 IgA appears to protect primary health care workers from COVID-19.European journal of immunology · 2022Article
- Article
- Pathophysiology of Eosinophilic Esophagitis.Gastroenterology · 2018Review
- Eosinophils from eosinophilic oesophagitis patients have T cell suppressive capacity and express FOXP3.Clinical and experimental immunology · 2017Article
- Tissue Remodeling in Chronic Eosinophilic Esophageal Inflammation: Parallels in Asthma and Therapeutic Perspectives.Frontiers in medicine · 2017Review
- Clinical and Biological Markers in Hypereosinophilic Syndromes.Frontiers in medicine · 2017Article
- Recent discoveries and emerging therapeutics in eosinophilic esophagitis.World journal of gastrointestinal pharmacology and therapeutics · 2016Review
- Biomarkers of the involvement of mast cells, basophils and eosinophils in asthma and allergic diseases.The World Allergy Organization journal · 2016Review
- Do We Know What Causes Eosinophilic Esophagitis? A Mechanistic Update.Current gastroenterology reports · 2015Review
- Translating new developments in eosinophilic esophagitis pathogenesis into clinical practice.Current treatment options in gastroenterology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Swallowed topical corticosteroids are the standard therapy for eosinophilic esophagitis (EoE) in adults. Eosinophils in the blood of untreated EoE patients have an activated phenotype. Our aim was to determine if corticosteroids restore the phenotype of eosinophils to a healthy phenotype and if certain cell-surface molecules on blood eosinophils correlate with eosinophilic infiltration of the esophagus. Levels of eight surface markers on eosinophils from treated and untreated EoE patients were determined by flow cytometry and analyzed using multivariate methods of pattern recognition. Corticosteroid-treated EoE patients' eosinophils had decreased levels of CD18 compared to both untreated patients and healthy controls, but maintained their activated phenotype. CD18 expression correlated positively with eosinophil numbers in the esophagus and promoted the adherence of eosinophils to ICAM-1, ICAM-2, and to endothelial cells. The diminished expression of CD18 may be one mechanism behind the reduced entry of eosinophils into the esophagus in corticosteroid-treated EoE patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.